2月18日,CSL Limited(ASX:CSL;USOTC:CSLLY)宣布已与礼来公司签订了一项独家许可协议,授予其开发和商业化抗白细胞介素-6(IL-6)单克隆抗体clazakizumab的某些权利。根据协议条款,CSL将保留开发和商业化clazakizumab的专有权,用于预防终末期肾病(ESKD)患者的心血管事件。CSL正在推进正在进行的POSIBIL6ESKD 3期临床试验(...
Source Link2月18日,CSL Limited(ASX:CSL;USOTC:CSLLY)宣布已与礼来公司签订了一项独家许可协议,授予其开发和商业化抗白细胞介素-6(IL-6)单克隆抗体clazakizumab的某些权利。根据协议条款,CSL将保留开发和商业化clazakizumab的专有权,用于预防终末期肾病(ESKD)患者的心血管事件。CSL正在推进正在进行的POSIBIL6ESKD 3期临床试验(...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.